Lazard Asset Management
EPZM

Lazard Asset Management’s Epizyme, Inc EPZM Stock Holding History

Lazard Asset Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-49,878
Closed -$57K – 2643
2022
Q1 		$57K Buy
+49,878
New +$81.3K ﹤0.01% 1681

Other funds holding EPZM

RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Lazard Asset Management's EPZM Position: Q2 2022 in Review

Lazard Asset Management sold out of Epizyme, Inc (EPZM) in Q2 2022, closing a stake of 49,878 shares — an estimated $57K sold.

Lazard Asset Management first reported a position in EPZM in Q1 2022 and held it in 1 quarter. The position peaked at $57K in Q1 2022. 93 funds tracked by Wall St. Rank hold EPZM as of Q2 2022.

  • Lazard Asset Management reported no remaining Epizyme, Inc position as of Q2 2022 after selling out during the quarter.
  • Lazard Asset Management sold 49,878 Epizyme, Inc shares in Q2 2022, an estimated $57K.
  • Lazard Asset Management first reported a position in Epizyme, Inc in Q1 2022 and held it in 1 quarter.
  • Lazard Asset Management's Epizyme, Inc position peaked at $57K in Q1 2022.
  • 93 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2022.

Based on Lazard Asset Management's 13F filing for Q2 2022, filed 9 Aug 2022.